Pharmaceutical Technology

OCTOBER 31, 2022

If approved, GSK’s GSK-3844766A will be the first vaccine to reach the market for the prevention of RSV in older adults, gaining a significant first-mover advantage. The post GSK speeds up the race to bring first RSV vaccine for older adults to market appeared first on Pharmaceutical Technology.

Vaccination 338

Vaccination Vaccine Marketing Trials 338

Pharmaceutical Technology

APRIL 3, 2023

The European Commission (EC) has granted marketing authorisation for Sandoz’s biosimilar Hyrimoz (adalimumab) citrate-free high-concentration formulation (HCF). With eight marketed biosimilars, Sandoz is offering the broadest biosimilar portfolio and is the leading biosimilars company in Europe, with more than two decades of experience.

Marketing 264

Marketing Medicine Packaging Packaging 264

Bio Pharma Dive

AUGUST 8, 2023

The Indianapolis drugmaker is now worth more than $500 billion, higher than any other pharmaceutical company, as analysts project lucrative markets for its obesity and Alzheimer's drugs.

Marketing 246

Marketing Sales Drugs 246

Pharmaceutical Technology

AUGUST 20, 2024

The top 20 biopharmaceutical companies demonstrated resilience during the second quarter (Q2) of 2024 as global markets and investor optimism improved with anticipation of a potential interest rate cut from the US Federal Reserve.

Marketing 263

Marketing Drugs 263

Pharmaceutical Technology

MAY 26, 2023

The immuno-oncology market continues to evolve as treatments establish their presence across different types of cancer, having seen approvals in multiple indications in the past decade. There are currently over 700 immuno-oncology products in Phase I-III of development in the eight major markets, said Chalk.

Marketing 264

Marketing Vaccination Vaccine Development 264

Pharmaceutical Technology

JULY 1, 2024

On 8 May, the UK was the world's first government to formally implement a new model for the funding and support of novel antibiotic commercialisation.

Marketing 299

Marketing 299

Pharmaceutical Technology

JULY 22, 2024

As the use of AI soared across healthcare, NVIDIA fit the bill in providing the necessary technology – and its stock tells the same story.

Marketing 344

Marketing 344

Bio Pharma Dive

JANUARY 17, 2024

The offering is the fifth outlined by a biotech startup this month, suggesting companies are becoming more willing to gauge investors’ appetite for new stock offerings.

Marketing 319

Marketing 319

Pharmaceutical Technology

APRIL 27, 2023

The European Commission’s (EC) long-anticipated pharma reform plans in the European Union have finally been unveiled , indicating a focus on improving access to medicines across the bloc while cutting down on market exclusivity.

Marketing 264

Marketing Medicine Production Clinical Trials 264

Pharmaceutical Technology

DECEMBER 10, 2024

The respiratory syncytial virus (RSV) prophylaxis market across the eight major markets (8MM) - comprising the US, the five major European markets (France, Germany, Italy, Spain, and the UK), Japan, and Australia - is forecast to grow from $582m in 2020 to $6.2bn in 2030 at a compound annual growth rate of 26.7%, with the paediatric and adult segments (..)

Marketing 147

Marketing 147

Pharmaceutical Technology

DECEMBER 5, 2024

LEO Pharma has gained marketing authorisation from the MHRA for Anzupgo to treat chronic hand eczema (CHE) in Great Britain.

Marketing 147

Marketing 147

Bio Pharma Dive

SEPTEMBER 26, 2024

The withdrawal comes as trial results indicate safety concerns with the drug, Oxbryta, which was first approved in the U.S.

Trials 285

Trials Drugs Marketing 285

Pharmaceutical Technology

JUNE 28, 2024

On 17 June, Amylyx acquired the rights to Eiger Biopharmaceutical’s experimental GLP-1 receptor antagonist, avexitide, for $35.1m.

Marketing 264

Marketing 264

Bio Pharma Dive

NOVEMBER 22, 2022

The British drugmaker has begun the process of withdrawing its multiple myeloma treatment Blenrep following a request from the FDA.

Marketing 321

Marketing Drugs 321

Bio Pharma Dive

OCTOBER 25, 2022

Treatment is now mostly of infants newly diagnosed with spinal muscular atrophy, as many of those previously eligible either already received Zolgensma or other drugs from Biogen and Roche.

Gene Therapy 298

Gene Therapy Sales Gene Marketing 298

Bio Pharma Dive

JULY 22, 2024

Private biotech company acquisitions are on their fastest pace in years, a trend some in the industry say is driven by the abundance of mature, but not yet public, drug startups.

Marketing 256

Marketing Drugs 256

Bio Pharma Dive

JANUARY 19, 2023

“What we’re experiencing now is the aftershock of the party that went on for the last three years,” said Ovid CEO Jeremy Levin in a BioPharma Dive panel that included former Sage head Jeff Jonas and biotech entrepreneur Greg Verdine.

Marketing 336

Marketing Drugs 336

Pharmaceutical Technology

DECEMBER 18, 2024

A new report identifies data content management as the primary driver of growth in the pharmaceuticals market.

Marketing 147

Marketing 147

Pharmaceutical Technology

OCTOBER 18, 2024

Late-stage pipeline products could drive combined sales of approximately $171.4 million by 2033 in the 8MM.

Sales 269

Sales Marketing Production 269

Bio Pharma Dive

MARCH 31, 2023

The biotech tools supplier is acquiring Polyplus, a French company that makes components essential to the viral vector backbones of gene therapies.

Gene Therapy 285

Gene Therapy Gene Marketing 285

Pharmaceutical Technology

SEPTEMBER 27, 2024

The US Food and Drug Administration (FDA) has announced the approval of Sanofi and Regeneron’s interleukin (IL)-4 and IL-13 monoclonal antibody, Dupixent, for the US market.

FDA Approval 162

FDA Approval Marketing Antibody Drugs 162

Pharmaceutical Technology

NOVEMBER 8, 2024

Leqembi is approved for Alzheimer’s patients in multiple territories, but questions remain over its cost-effectiveness.

Marketing 240

Marketing 240

Pharmaceutical Technology

AUGUST 12, 2024

As antibody drug conjugate (ADC)-centred deals dominate the oncology space, biotechs are using newer targets and linkers to differentiate themselves.

Pharma Companies 264

Pharma Companies Antibody Marketing Drugs 264

Pharmaceutical Technology

JUNE 27, 2024

Data showed that Ohtuvayre significantly improved dyspnea compared to placebo in as little as six weeks and maintained this over 24 weeks.

Marketing 244

Marketing 244

Pharmaceutical Technology

MAY 2, 2024

Novo Nordisk noted a 22% boost in sales owing to increased sales of GLP-1 agonists and other obesity products.

Sales 246

Sales Marketing Production 246

Pharmaceutical Technology

JULY 22, 2024

As the use of AI soared across healthcare, NVIDIA fit the bill in providing the necessary technology – and its stock tells the same story.

Marketing 245

Marketing 245

AuroBlog - Aurous Healthcare Clinical Trials blog

OCTOBER 15, 2024

(Abdullah Durmaz/Getty Images) In just a few years, brand-name injectable drugs such as Ozempic, Wegovy, Mounjaro and Zepbound have rocketed to fame as billion-dollar annual sellers for weight loss as well as to control blood sugar levels and reduce the risk of heart disease. But the price of these injections is steep: They cost about […]

Marketing 244

Marketing Branding Drugs Clinical Trials 244

Pharmaceutical Technology

NOVEMBER 6, 2024

The top 20 biopharmaceutical companies demonstrated signs of recovery during the third quarter (Q3) of 2024 as investor optimism improved following the interest rate cuts by the US Federal Reserve in September 2024.

Marketing 263

Marketing Drugs 263

Pharmaceutical Technology

JANUARY 21, 2024

CDMOs, who cater to the requirements of multiple companies and develop platform processes to achieve the much-needed economy of scale, are being seen as a possible solution.

Manufacturing 246

Manufacturing Marketing Development 246

Pharmaceutical Technology

DECEMBER 5, 2023

Professor Timothy Mackey talks about the recent reports of fraudulent Ozempic pens and the challenges in chasing drug counterfeiters.

Drugs 278

Drugs Marketing 278

Pharmaceutical Technology

SEPTEMBER 1, 2023

Novo Nordisk's obesity drugs are driving Danish growth as well as record profits as the company becomes second-most valuable in Europe.

Drugs 264

Drugs Marketing 264

Pharmaceutical Technology

NOVEMBER 21, 2024

The EC has granted marketing authorisation for Pfizer's anti-tissue factor pathway inhibitor (anti-TFPI), HYMPAVZI to treat haemophilia.

Marketing 130

Marketing 130

Bio Pharma Dive

NOVEMBER 22, 2024

The approval of Attruby for transthyretin amyloidosis with cardiomyopathy begins a battle for control of a lucrative market that investors have been skeptical BridgeBio can win.

Drugs 312

Drugs Marketing 312

Bio Pharma Dive

DECEMBER 4, 2024

Results from the head-to-head study showed treatment with Zepbound resulted in 47% greater relative weight loss than Wegovy, a finding that could advantage Lilly in the companies’ market competition.

Drug Trials 317

Drug Trials Trials Drugs Marketing 317

Bio Pharma Dive

MARCH 8, 2024

The results have led Amylyx to pause promotion of Relyvrio and potentially pull it from the market in the coming weeks, a major blow to the company and ALS patients.

Drugs 344

Drugs Marketing 344

Bio Pharma Dive

FEBRUARY 2, 2023

The company’s lead drug could be an oral alternative to marketed diabetes and obesity drugs from Novo Nordisk and Eli Lilly.

Marketing 360

Marketing Drugs 360

Bio Pharma Dive

NOVEMBER 11, 2024

Negative drug results cost AbbVie billions of dollars in market value and convinced analysts that Bristol Myers had placed a better bet in buying Karuna Therapeutics.

Drugs 328

Drugs Marketing 328